|
|
Ann Surg. 1988 May; 207(5): 581–589. | PMCID: PMC1493478 |
Splenectomy in hematologic disorders. The ever-changing indications. M C Wilhelm, R E Jones, R McGehee, J S Mitchener, W R Sandusky, and C E Hess Department of Surgery, University of Virginia Medical Center, Charlottesville 22908. Abstract A comparison between a series of splenectomies performed at the University of Virginia Medical Center for hematologic disorders between 1946 and 1962 (Series I) and 1963 and 1982 (Series II) is presented. Four hundred splenectomies (20 per year) were performed between 1963 and 1982 compared with 94 (5.5 per year) between 1946 and 1962. Also noted in Series II was a sharp decline in the number performed each year between 1974 and 1983. The major factor responsible for these observations was the evolution of the staging laparotomy for malignant lymphomas, particularly Hodgkin's disease, and the decline in the average annual incidence of staging laparotomies since 1974. Staging laparotomy currently is rarely done for non-Hodgkin's lymphomas. Also contributing to the changes noted was an increase in the total number but subsequent fall in the annual incidence of splenectomy for hereditary spherocytosis, idiopathic hypersplenism, and myeloproliferative disorders in Series II. The average number of splenectomies for idiopathic thrombocytopenic purpura increased from 1.1 per year in Series I to 3.6 per year in Series II; the annual incidence during the study period of Series II, however, remained constant. The total number of splenectomies for hairy cell leukemia and Felty's syndrome increased from zero in Series I to 12 and 17, respectively, in Series II, whereas the number of miscellaneous reasons dropped from 29 (1.7 per year) in Series I to 15 (0.75 per year) in Series II. The mortality rate in Series I was 6.3% compared with 4.0% in Series II. No deaths occurred in Series II after 1979. Indications for splenectomy in Series II were for diagnostic purposes in 3.2%, therapeutic in 56.5%, staging in 39.5%, and restaging in 0.8%. Accessory spleens were found in 49 (12.5%) in Series II. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Glatstein E, Guernsey JM, Rosenberg SA, Kaplan HS. The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer. 1969 Oct;24(4):709–718. [PubMed]
- Sandusky WR, Jones RC, Jr, Horsley JS, 3rd, Marsh WL, Jr, Tillack TW, Tegtmeyer CJ, Hess CE. Staging laparotomy in Hodgkin's disease. Ann Surg. 1978 May;187(5):485–489. [PubMed]
- Goffinet DR, Warnke R, Dunnick NR, Castellino R, Glatstein E, Nelsen TS, Dorfman RF, Rosenberg SA, Kaplan HS. Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphomas. Cancer Treat Rep. 1977 Sep;61(6):981–992. [PubMed]
- Chabner BA, Johnson RE, Young RC, Canellos GP, Hubbard SP, Johnson SK, DeVita VT. Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Cancer. 1978 Aug;42(2 Suppl):922–925. [PubMed]
- SANDUSKY WR, LEAVELL BS, BENJAMIN BI. SPLENECTOMY: INDICATIONS AND RESULTS IN HEMATOLOGIC DISORDERS. Ann Surg. 1964 May;159:695–710. [PubMed]
- Hess CE, Ayers CR, Sandusky WR, Carpenter MA, Wetzel RA, Mohler DN. Mechanism of dilutional anemia in massive splenomegaly. Blood. 1976 Apr;47(4):629–644. [PubMed]
- Thompson RL, Moore RA, Hess CE, Wheby MS, Leavell BS. Idiopathic thrombocytopenic purpura. Long-term results of treatment and the prognostic significance of response to corticosteroids. Arch Intern Med. 1972 Nov;130(5):730–734. [PubMed]
- Mohler DN, Wheby MS. Hemochromatosis heterozygotes may have significant iron overload when they also have hereditary spherocytosis. Am J Med Sci. 1986 Nov;292(5):320–324. [PubMed]
- Moore RA, Brunner CM, Sandusky WR, Leavell BS. Felty's syndrome: long-term follow-up after splenectomy. Ann Intern Med. 1971 Sep;75(3):381–385. [PubMed]
- Bukowski RM. Thrombotic thrombocytopenic purpura: a review. Prog Hemost Thromb. 1982;6:287–337. [PubMed]
- Stewart FM, Williamson BR, Innes DJ, Hess CE. Residual tumor masses following treatment for advanced histiocytic lymphoma. Diagnostic and therapeutic implications. Cancer. 1985 Feb 1;55(3):620–623. [PubMed]
- Schwartz SI, Hoepp LM, Sachs S. Splenectomy for thrombocytopenia. Surgery. 1980 Oct;88(4):497–506. [PubMed]
- Cola B, Tonielli E, Sacco S, Brulatti M, Franchini A. Surgical treatment of chronic idiopathic thrombocytopenic purpura: results in 107 cases. Int Surg. 1986 Jul–Sep;71(3):195–198. [PubMed]
- Coon WW. Splenectomy for idiopathic thrombocytopenic purpura. Surg Gynecol Obstet. 1987 Mar;164(3):225–229. [PubMed]
- Mitchell A, Morris PJ. Surgery of the spleen. Clin Haematol. 1983 Jun;12(2):565–590. [PubMed]
- Schwartz SI. Splenectomy for hematologic disease. Surg Clin North Am. 1981 Feb;61(1):117–125. [PubMed]
- Dameshek HL, Ellis LD. Hematologic indications for splenectomy. Surg Clin North Am. 1975 Apr;55(2):253–275. [PubMed]
- Dawson AA, Jones PF, King DJ. Splenectomy in the management of haematological disease. Br J Surg. 1987 May;74(5):353–357. [PubMed]
- Musser G, Lazar G, Hocking W, Busuttil RW. Splenectomy for hematologic disease. The UCLA experience with 306 patients. Ann Surg. 1984 Jul;200(1):40–45. [PubMed]
|